Abstract:Introduction: Noninsulin dependent diabetes mellitus (NIDDM) or Diabetes Type 2 is a major health challenge worldwide. In 2014 the World Health Organization (WHO) revealed that the percentage of adults with fasting glucose ≥ 7.0 mmol/L accounts for 9% globally. Moreover, the highest percentage was in the Eastern Mediterranean Region with 26.8 ± 0.4%. Type 2 diabetes is a complex metabolic disorder associated with high level of glucose in blood (hyperglycemia) which lead to long-term pathogenic conditions such as: neuropathy, retinopathy, nephropathy and a consequent decrease in quality of life and increased mortality rate. Starch is the main source of energy for most living organisms; in humans it is digested over several stages that involve different amylolytic enzymes, such as α-Amylase and α-Glucosidase. Alpha Amylase is the major secretory product (about 5–6%) of the pancreas and salivary glands, playing a core role in starch and glycogen digestion. The control of postprandial hyperglycemia is an important strategy in the management of Type 2 diabetes; lifestyle modification and/or the use of medications such as insulin and α-Glucosidase inhibitors are the available treatments to date. Acrabose is a prominently used α-Glucosidase inhibitor for diabetes and obesity control, however it has many side effects and limitations. Numerous in vivo studies (REFS) have shown that many plant extracts inhibit the key enzymes of digestion (α-Amylase and α-Glucosidase) and the use of naturally occurring inhibitors is potentially the most effective and safest approaches for treating diabetes. Aims: Short-term aim: To clone, express and purify human α-Amylase protein using different yeast expression systems. Followed by protein (c0)crystallization and structural analysis. Long-term aim: Screening natural products (plant extracts) based on their traditional use followed by co-crystallisation of selected inhibitors. This will be complemented by inhibitors designed in silico based on the ANCHOR.QUERY approach (REF). Finally, identified compounds will be characterised by biophysical and kinetic studies. Methodology: Human α-Amylase has been cloned into two vectors pHIPZ-4 and pPIC9k, each with its own set of primers, restriction enzymes and dedicated expression host (pHIPZ-4: Hansenula polymorpha and pPIC9k: Pichia pastoris, respectively). After transformation, the grown colonies were tested for the presence of the target gene by colony PCR and digestion with cloning enzymes. Positive colonies were re-inoculated in growth media and recombinant plasmid was recovered. The plasmids were then transformed into competent yeast cells by electroporation. For H. polymorpha, cells were grown in minimal media with glucose (MM/G) for two days followed by induction of expression with 0.5% (v/v) MeOH. Protein was purified by lysing the cells and passing the lysate through Ni-NTA beads. Finally protein was identified with by Western blot using HisProbe-HRP antibody. Results: Human α-Amylase gene was successfully cloned in both vectors pHIPZ-4 and pPIC9k according to colony PCR and digestion judgment on Agarose gel. However, the expression of α-Amylase protein in H. polymorpha system is insufficient to support the downstream work. Analysis of secreted expression using Pichia pastoris is currently underway and the results will be reported at the meeting. Conclusion: Human α-Amylase was successfully cloned in both vectors and stably transformed to E. coli competent cells. The positive colonies were confirmed for the present of targeted gene then transformed to yeast cells.

Taxonomy of the Streptomyces Strain Zg0656 That Produces Acarviostatin Alpha-Amylase Inhibitors and Analysis of Their Effects on Blood Glucose Levels in Mammalian Systems

Separation, Determination and Antifungal Activity Test of the Products from A New Bacillus Amyloliquefaciens

Identification and proteomic analysis of a novel gossypol-degrading fungal strain.

[Construction of a New Brewing Yeast Strain with Secretive Alpha-Amylase Activity and Reduced Diacetyl Production].

Profiling of Acarviostatin Family Secondary Metabolites Secreted by Streptomyces Coelicoflavus ZG0656 Using Ultraperformance Liquid Chromatography Coupled with Electrospray Ionization Mass Spectrometry.

Three New Isoflavonoid Glycosides From The Mangrove-Derived Actinomycete Micromonospora Aurantiaca 110b

Anastomotic dehiscence after anterior resection of rectum and sigmoid

Cytotoxic and Antifungal Staurosporine Derivatives from Marine-Derived Actinomycete Streptomyces Sp. ZS-A121

Inhibition mechanism of alpha-amylase, a diabetes target, by a steroidal pregnane and pregnane glycosides derived from Gongronema latifolium Benth

Identification and Structural Analysis of Natural Product Inhibitors of Human Alpha-Amylase to Target Diabetes Mellitus

Comparative proteome analysis of Actinoplanes utahensis grown on various saccharides based on 2D-DIGE and MALDI-TOF/TOF-MS

Biochemistry of peroxisomes.

α-Glucosidase Inhibitors from Two Mangrove-Derived Actinomycetes

Optimization, purification and characterization of α-glucosidase inhibitors from Streptomyces costaricanus EBL.HB6 isolated in Vietnam

Metabolites extracted from microorganisms as potential inhibitors of glycosidases (α-glucosidase and α-amylase): A review

[Participation of various types of serotonin receptors in the regulation of drinking behavior and salt appetite in rats].

Screening of Novel Potential Antidiabetic Lactobacillus Plantarum Strains Based on in Vitro and in Vivo Investigations

Isolation, Identification and Mutation Breeding of an Endophytic Strain Producing α-Glucosidase Inhibitor from Mulberry Leaf

Advances in microbial exopolysaccharides as α-amylase inhibitors: Effects, structure-activity relationships, and anti-diabetic effects in vivo

Purification and biological evaluation of the metabolites produced by Streptomyces sp. TK-VL_333

Multi-target anti-diabetic styrylpyrones from Phellinus igniarius: Inhibition of α-glucosidase, protein glycation, and oxidative stress